Abstract

Drug-based monotherapy provides limited clinical benefits in polygenic disorders, such as androgenetic alopecia. Possible benefits must be measured against non-trivial risks of negative side effects. Several well-controlled, peer-reviewed, basic science studies have demonstrated novel mechanisms of action and potential utility for natural-based phytochemicals in the treatment of androgen-mediated disorders, including androgenetic alopecia. Yet, due to phytochemical instability, volatility, and incompatibility, the bridge from in vitro potential to clinical efficacy remains largely unmet. Recent advances in nanomaterial manipulation provide enhanced platforms, such as cyclodextrins, in which these phytochemicals may be enveloped and delivered without triggering the loss of intended function. Unexpected, positive results of an uncontrolled case series for a cyclodextrin-enabled, natural-based formula containing γ linolenic acid, β-Sitosterol, epigallocatechin gallate, and genistein, administered concomitantly via oral and topical form in two androgenetic alopecia-affected, male subjects over the course of 270 days were found. At baseline, significant baldness in the vertex scalp of both subjects was observed. Subsequent 90-day time points demonstrated marked hair thickening. On treatment day 270 (conclusion), scalp hair loss was no longer evident in either patient. Particularly in the setting of a disorders, such as androgenetic alopecia, nano-complexed, botanically-based compositions may offer beneficial adjunctives or alternatives to traditional drug-based/surgical medical treatments.

Highlights

  • Several hair loss phenotypes occur in humans, with androgenetic alopecia (AGA) or common pattern hair loss constituting the most prevalent form by far [1]

  • Results from this study showed that epigallocatechin gallate (EGCG) protects DHT-induced cell death by regulating the cellular miRNA expression profile, thereby attenuating DHT-mediated cell death and growth arrest

  • The utility utility of of oral oral and and topical topical drug-based drug-based hair hair loss loss treatment treatment products products has has been been demonstrably demonstrably proven in well-controlled, peer-reviewed research studies

Read more

Summary

Introduction

Several hair loss phenotypes occur in humans, with androgenetic alopecia (AGA) or common pattern hair loss constituting the most prevalent form by far [1]. The connection between AGA and age-related disease remains inconclusive; tantalizing clues suggest a linkage between these two conditions. Individuals with vertex baldness are at a statistically significant increased risk of developing prostate cancer [2]. Both men and women may be affected by AGA as a result of similar genetic and hormonal triggers. The expression pattern differs according to epigenetic and gender-specific variables. Males may begin losing hair in their late teens to early 20s, whereas it is unusual for a woman to experience

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call